Patent assignee · US · COMPANY

MEDAREX INC.

🏢 View company profile →
133Patents
72Active
133Granted
52Portfolio score

Filing activity: Mar 7, 1991 → Jan 14, 2016 · 63 expiring within 5 years

Most-cited patents

PatentTitleAreaCited byStatus
US8008449B2 Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics Emerging Cross-Sectional Technologies 812 Active
US7943743B2 Human monoclonal antibodies to programmed death ligand 1 (PD-L1) Emerging Cross-Sectional Technologies 541 Active
US5837243A Therapeutic compounds comprised of anti-Fc receptor antibodies Chemistry; Metallurgy 255 Expired
US6984720B1 Human CTLA-4 antibodies Emerging Cross-Sectional Technologies 252 Expired
US5922845A Therapeutic multispecific compounds comprised of anti-Fc.alpha. receptor antibodies Chemistry; Metallurgy 204 Expired
US7041870B2 Transgenic transchromosomal rodents for making human antibodies Chemistry; Metallurgy 173 Expired
US6063116A Modulation of cell proliferation and wound healing Human Necessities 161 Expired
US7129261B2 Cytotoxic agents Chemistry; Metallurgy 160 Expired
US8383796B2 Nucleic acids encoding monoclonal antibodies to programmed death ligand 1 (PD-L1) Emerging Cross-Sectional Technologies 148 Active
US6989452B2 Disulfide prodrugs and linkers and stabilizers useful therefor Chemistry; Metallurgy 146 Expired
US7501552B2 Transgenic non-human animals for producing chimeric antibodies Chemistry; Metallurgy 145 Expired
US7087600B2 Peptidyl prodrugs and linkers and stabilizers useful therefor Chemistry; Metallurgy 143 Expired
US7691962B2 Chemical linkers and conjugates thereof Chemistry; Metallurgy 138 Active
US7605238B2 Human CTLA-4 antibodies and their uses Emerging Cross-Sectional Technologies 122 Expired
US7517903B2 Cytotoxic compounds and conjugates Chemistry; Metallurgy 114 Active
US7507420B2 Peptidyl prodrugs and linkers and stabilizers useful therefor Chemistry; Metallurgy 107 Active
US7910798B2 Transgenic animals expressing chimeric antibodies for use in preparing human antibodies Chemistry; Metallurgy 106 Active
US6270765A Therapeutic compounds comprised of anti-Fc receptor antibodies Chemistry; Metallurgy 96 Expired
US7498302B2 Disulfide prodrugs and linkers and stabilizers useful therefor Chemistry; Metallurgy 93 Expired
US8158419B2 Transgenic non-human animals for producing chimeric antibodies Chemistry; Metallurgy 90 Active
US6111166A Transgenic mice expressing human Fc.alpha. and .beta. receptors Human Necessities 81 Expired
US7456264B2 Human monoclonal antibodies against Bacillus anthracis protective antigen Chemistry; Metallurgy 70 Expired
US6365161B1 Therapeutic compounds comprised of anti-FC receptor binding agents Chemistry; Metallurgy 60 Expired
US8017114B2 Human CTLA-4 antibodies and their uses Emerging Cross-Sectional Technologies 55 Active
US8124738B2 Human monoclonal antibodies to CD70 Emerging Cross-Sectional Technologies 51 Active

Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.